Grail GRAL 深 沪
交易中 05-14 10:58:10 美东时间
61.34
+0.870
+1.44%
华盛通- 最 高62.74
- 今 开60.47
- 成交量 17.08万股
- 最 低 60.10
- 昨 收 60.47
- 总市值 26.33亿
- 52周最高 118.84
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 29.95
- 委 比 76.00%
- 总股本 4291.66万
- 历史最高 118.84
- 量 比 1.72
- 振 幅 4.37%
- 历史最低 12.33
- 每 手 1
- 风险率 25.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Digimarc Reports Q1 2026 Results: Full Earnings Call Transcript
On Tuesday, Digimarc (NASDAQ:DMRC) discussed first-quarter financial results du...
05-13 05:55
财报速睇 | Grail 2026财年Q1营收0.41亿美元，同比增长28.1%；归母净利润亏损0.93亿美元，同比亏损缩窄12.3%
华盛资讯5月8日讯，Grail公布2026财年Q1业绩，公司Q1营收0.41亿美元，同比增长28.1%，归母净利润亏损0.93亿美元，同比亏损缩窄12.3%。
05-08 13:17
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
GRAIL shares are trading higher after the company reported better-than-expected Q1 financial results.
GRAIL shares are trading higher after the company reported better-than-expected...
05-06 23:39
Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $56
Piper Sandler analyst David Westenberg maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price target from $54 to $56.
05-06 23:35
财报速睇 | Grail 2026财年Q1营收0.41亿美元，同比增长28.1%；归母净利润亏损0.93亿美元，同比亏损缩窄12.3%
华盛资讯5月6日讯，Grail公布2026财年Q1业绩，公司Q1营收0.41亿美元，同比增长28.1%，归母净利润亏损0.93亿美元，同比亏损缩窄12.3%。
05-06 05:18
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
Porsche 918 Spyder Weissach Tops Broad Arrow’s $20 Million Air|Water Auction
Broad Arrow Auctions' 2026 Porsche Air|Water Auction achieved $20 million in total sales with an 84% sell-through rate, marking its best performance to date. The top sale was the 2015 Porsche 918 Spyder Weissach at $4.68 million, followed by the 2025 RUF SCR at $2.095 million. Other highlights included two Singer Reimagined 911s and rare Power Kit-equipped 911s. The auction, held during the Air|Water event, featured nearly 50% first-time bidders ...
04-28 16:56
GRAIL To Reveal New Data From NHS-Galleri And PATHFINDER 2 At 2026 ASCO Annual Meeting
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further
04-22 04:55
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, April 15, 2026 /PRNewswire/ -- Grail, Inc. (NA...
04-15 21:00
